Phenylephrine

KENVUE SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Kenvue To Contact Him Directly To Discuss Their Options

Retrieved on: 
Saturday, November 4, 2023
FDA, Complaint, NYSE, KVUE, Registration statement, Court, Advertising, Woman, PE, LLP, Phenylephrine, Prospectus, Risk, Johnson & Johnson, Defendant, Security (finance), Pharmaceutical industry, IPO

NEW YORK, Nov. 04, 2023 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Kenvue Inc. (“Kenvue” or the “Company”) (NYSE: KVUE) and reminds investors of the December 8, 2023 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Key Points: 
  • Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • In May 2023, Kenvue conducted an IPO, offering approximately 171,812,560 shares of Kenvue common stock to the investing public at $22.00 per share.
  • Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding Kenvue’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Kenvue, Inc. (KVUE) Faces Lawsuit Over Possible Disclosure Violations- Hagens Berman

Retrieved on: 
Friday, November 3, 2023
Person, FDA, IPO, NYSE, KVUE, PE, Phenylephrine, Risk, Hagens Berman, SAN, Security (finance), Pharmaceutical industry, Life insurance

On or around Sept. 12, 2023, the FDA published a briefing document announcing that it was convening an advisory committee to discuss efficacy data available for orally administered phenylephrine as a nasal decongestant.

Key Points: 
  • On or around Sept. 12, 2023, the FDA published a briefing document announcing that it was convening an advisory committee to discuss efficacy data available for orally administered phenylephrine as a nasal decongestant.
  • “We’re focused on investors’ losses and investigating whether Kenvue adequately disclosed commercial risks related to its products containing PE,” said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC.
  • For more information, call Reed Kathrein at 844-916-0895 or email [email protected] .

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Kenvue Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – KVUE

Retrieved on: 
Thursday, November 2, 2023
Titan, Register, NYSE, KVUE, Registration statement, Court, I-Space (Chinese company), Advertising, Phenylephrine, Prospectus, Insurance, Tobacco, IPO

WHAT TO DO NEXT: To join the Kenvue class action, go to https://rosenlegal.com/submit-form/?case_id=19241 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Kenvue class action, go to https://rosenlegal.com/submit-form/?case_id=19241 or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Kenvue Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of December 8, 2023 – (NYSE: KVUE)

Retrieved on: 
Thursday, November 2, 2023
Person, Fraud, Phenylephrine, Prospectus, Risk, CLASS, NEXT, KVUE, Holding company, Security (finance), IPO

DEADLINE: December 8, 2023 Shareholders should not delay in registering for this class action.

Key Points: 
  • DEADLINE: December 8, 2023 Shareholders should not delay in registering for this class action.
  • The deadline to seek to be a lead plaintiff is December 8, 2023.
  • The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices.
  • The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship.

Eyenovia Announces FDA Approval of Coastline International as Contract Manufacturer to Initiate Mydcombi Commercial Production

Retrieved on: 
Thursday, November 2, 2023
FDA, Phenylephrine, Mydriasis, Pain, Surgeon, Risk, Tropicamide, Inflammation, Shanda, Presbyopia, Pharmaceutical industry, Medical device

Coastline will manufacture cartridge subassemblies for Mydcombi, the only FDA-approved tropicamide and phenylephrine hydrochloride fixed combination for mydriasis (office-based pupil dilation).

Key Points: 
  • Coastline will manufacture cartridge subassemblies for Mydcombi, the only FDA-approved tropicamide and phenylephrine hydrochloride fixed combination for mydriasis (office-based pupil dilation).
  • “One of the many benefits of Mydcombi is that, unlike eye droppers, there is no protruding tip that can come in contact with the patient’s eye.
  • “We believe Mydcombi, because of its design, addresses this challenge and can provide significant cost savings to doctors and surgical centers.
  • With FDA approval of Coastline, our manufacturing capabilities are in place, and we anticipate initiating Mydcombi commercial production imminently with the goal of having product available to ship in January of 2024.”

DEADLINE ALERT for GCT, DLO, AAP, and KVUE: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

Retrieved on: 
Thursday, November 2, 2023
Suite, Register, Registration statement, Disclosure, Law, DLocal, Phenylephrine, Risk, Investment, Perception, Defendant, Security (finance), Pharmaceutical industry, IPO

LOS ANGELES, Nov. 02, 2023 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.

Key Points: 
  • LOS ANGELES, Nov. 02, 2023 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.
  • Investors suffering losses on their investments are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights in these class actions at 310-914-5007 or by email to [email protected] .
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
  • The Law Offices of Frank R. Cruz, Los Angeles

DEADLINE ALERT for AAP, KVUE, CGRN, NKLA: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

Retrieved on: 
Wednesday, November 1, 2023
Suite, Telephone, Law, Bank statement, Phenylephrine, Risk, People's Law Office, Safety, Investment, Class, Perception, Security (finance), Risk management, IPO

BENSALEM, Pa., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.

Key Points: 
  • BENSALEM, Pa., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.
  • Investors have until the deadlines listed below to file a lead plaintiff motion.
  • Investors suffering losses on their investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in these class actions at 888-638-4847 or by email to [email protected] .
  • Law Offices of Howard G. Smith

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Kenvue Inc. (KVUE) Investors of a Class Action Lawsuit and Upcoming Deadline

Retrieved on: 
Wednesday, November 1, 2023
NYSE, KVUE, Person, Telephone, CASE, Court, NEXT, LLP, Phenylephrine, Prospectus, Risk, Levi, COST, CLASS, IPO

NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Kenvue Inc. ("Kenvue" or the "Company") (NYSE: KVUE) of a class action securities lawsuit.

Key Points: 
  • NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Kenvue Inc. ("Kenvue" or the "Company") (NYSE: KVUE) of a class action securities lawsuit.
  • CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Kenvue investors who were adversely affected by alleged securities fraud.
  • Follow the link below to get more information and be contacted by a member of our team:
    KVUE investors may also contact Joseph E. Levi, Esq.
  • For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

KENVUE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Kenvue Inc. and Encourages Investors to Contact the Firm

Retrieved on: 
Wednesday, November 1, 2023
IPO, Register, NYSE, KVUE, Person, Telephone, Court, P.C, Phenylephrine, Prospectus, Risk, District court, Security (finance)

Investors have until December 8, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until December 8, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Click here to participate in the action.
  • If you purchased or otherwise acquired Kenvue shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at [email protected] , telephone at (212) 355-4648, or by filling out this contact form .
  • There is no cost or obligation to you.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Kenvue Inc. (KVUE)

Retrieved on: 
Tuesday, October 31, 2023
Suite, FDA, Nasal, Register, NYSE, KVUE, Registration statement, News, Court, PE, Phenylephrine, Prospectus, GPM, Nasal congestion, Risk, Johnson & Johnson, Defendant, Security (finance), Pharmaceutical industry, IPO

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • In May 2023, Kenvue conducted an IPO, offering approximately 171,812,560 shares of Kenvue common stock to the investing public at $22.00 per share.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • Glancy Prongay & Murray LLP, Los Angeles